CHRS - CIK 0001512762
Coherus BioSciences, Inc. (CHRS) reported revenue of $42.17M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $42.17M | +59.8% |
| FY 2024 | $26.39M | +2066.6% |
| FY 2023 | $1.22M | -99.4% |
| FY 2022 | $211.04M | -35.4% |
| FY 2021 | $326.55M | -31.4% |
| FY 2020 | $475.82M | +33.6% |
| FY 2019 | $356.07M | - |
| FY 2018 | $0.00 | -100.0% |
| FY 2017 |
Coherus BioSciences, Inc. (CHRS) reported revenue of $42.17M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Coherus BioSciences, Inc.'s revenue grew from $1.90M to $42.17M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.56M |
| -99.2% |
| FY 2016 | $190.11M | +532.8% |
| FY 2015 | $30.04M | -3.4% |
| FY 2014 | $31.11M | +1030.7% |
| FY 2013 | $2.75M | +44.9% |
| FY 2012 | $1.90M | - |